Jacqueline McBride

6.6k total citations · 1 hit paper
46 papers, 4.6k citations indexed

About

Jacqueline McBride is a scholar working on Epidemiology, Genetics and Immunology. According to data from OpenAlex, Jacqueline McBride has authored 46 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 14 papers in Genetics and 14 papers in Immunology. Recurrent topics in Jacqueline McBride's work include Inflammatory Bowel Disease (12 papers), Influenza Virus Research Studies (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Jacqueline McBride is often cited by papers focused on Inflammatory Bowel Disease (12 papers), Influenza Virus Research Studies (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Jacqueline McBride collaborates with scholars based in United States, Canada and France. Jacqueline McBride's co-authors include Wyne P. Lee, Sanjeev Mariathasan, David S. Weiss, Denise M. Monack, Yvette Weinrauch, Karen O’Rourke, Kim Newton, Meron Roose-Girma, Vishva M. Dixit and Romeo Maciuca and has published in prestigious journals such as Nature, Nature Communications and Blood.

In The Last Decade

Jacqueline McBride

44 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cryopyrin activates the inflammasome in response to toxins and ATP

2006 2.5k citations Jacqueline McBride et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacqueline McBride United States	24	2.4k	2.3k	708	675	521	46	4.6k
Caroline A. Jefferies Ireland	36	3.4k 1.4×	1.7k 0.8×	565 0.8×	705 1.0×	460 0.9×	76	5.1k
Fernando Bazán France	20	3.9k 1.6×	1.5k 0.7×	556 0.8×	1.4k 2.1×	294 0.6×	68	6.7k
Lauri Diehl United States	38	2.5k 1.0×	1.3k 0.6×	1.1k 1.5×	503 0.7×	510 1.0×	63	5.0k
Patrizia Scapini Italy	33	3.5k 1.5×	1.1k 0.5×	396 0.6×	1.1k 1.6×	344 0.7×	50	5.0k
Daniela Bosisio Italy	37	3.3k 1.4×	1.4k 0.6×	536 0.8×	840 1.2×	499 1.0×	74	5.2k
Hartmut Engelmann Israel	32	3.5k 1.4×	1.4k 0.6×	762 1.1×	940 1.4×	557 1.1×	48	5.6k
Stefania Gallucci United States	25	2.5k 1.0×	1.2k 0.5×	344 0.5×	495 0.7×	357 0.7×	57	4.0k
Alexander R. Abbas United States	21	2.6k 1.1×	1.1k 0.5×	391 0.6×	616 0.9×	394 0.8×	32	5.3k
Kazunaga Agematsu Japan	42	3.2k 1.3×	1.3k 0.6×	632 0.9×	427 0.6×	289 0.6×	135	5.1k
Dmitry V. Kuprash Russia	35	2.7k 1.1×	1.3k 0.5×	434 0.6×	939 1.4×	180 0.3×	145	4.4k

Countries citing papers authored by Jacqueline McBride

Since Specialization

Citations

This map shows the geographic impact of Jacqueline McBride's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline McBride with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline McBride more than expected).

Fields of papers citing papers by Jacqueline McBride

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline McBride. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline McBride. The network helps show where Jacqueline McBride may publish in the future.

Co-authorship network of co-authors of Jacqueline McBride

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline McBride. A scholar is included among the top collaborators of Jacqueline McBride based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline McBride. Jacqueline McBride is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allegretti, Jessica R., Stefan Schreiber, Laurent Peyrin‐Biroulet, et al.. (2025). Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial. The Lancet. Gastroenterology & hepatology. 10(10). 882–895.

Păun, Andrei, et al.. (2025). P0928 Patient endotypes in ulcerative colitis revealed by longitudinal symptom trajectories under therapy. Journal of Crohn s and Colitis. 19(Supplement_1). i1742–i1742. 1 indexed citations

Harder, Brandon, Annemarie Lekkerkerker, Jason A. Hackney, et al.. (2024). Comprehensive profiling of the human fecal proteome from IBD patients with DIA‐MS enables evaluation of disease‐relevant proteins. PROTEOMICS - CLINICAL APPLICATIONS. 18(5). e2300075–e2300075. 4 indexed citations

Tamburini, Fiona B., Anupriya Tripathi, Maxwell P. Gold, et al.. (2024). Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy. Journal of Crohn s and Colitis. 18(11). 1819–1831. 4 indexed citations

Danese, Silvio, Michael E. Rothenberg, Jeremy J. Lim, et al.. (2024). A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 23(8). 1387–1397. 1 indexed citations

Shivram, Haridha, Jason A. Hackney, Carrie M. Rosenberger, et al.. (2023). Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19. iScience. 26(9). 107597–107597. 3 indexed citations

Bauer, Rebecca N., Anastasia Teterina, Haridha Shivram, et al.. (2023). Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID‐19. Clinical and Translational Science. 16(6). 1049–1062. 6 indexed citations

Levitte, Steven, Franklin Peale, Iny Jhun, Jacqueline McBride, & Margaret Neighbors. (2023). Local Pentraxin-2 Deficit Is a Feature of Intestinal Fibrosis in Crohn’s Disease. Digestive Diseases and Sciences. 68(7). 2975–2980. 2 indexed citations

Tang, Fei, Rebecca Kunder, Tom Chu, et al.. (2023). First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers. Clinical and Translational Science. 16(9). 1653–1666. 37 indexed citations

10.

Keir, Mary, Franklin Fuh, Ryan Ichikawa, et al.. (2021). Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease. The Journal of Immunology. 207(9). 2245–2254. 39 indexed citations

11.

Dotan, Iris, Matthieu Allez, Silvio Danese, et al.. (2019). The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti‐integrin therapies. Medicinal Research Reviews. 40(1). 245–262. 59 indexed citations

12.

Becker, Emily, Franklin Fuh, Philipp Tripal, et al.. (2019). Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Frontiers in Pharmacology. 10. 39–39. 31 indexed citations

13.

Tang, Meina, Mary Keir, Rich Erickson, et al.. (2018). Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 47(11). 1440–1452. 26 indexed citations

14.

Lau, Janet, Jeanne Cheung, Armando Navarro, et al.. (2017). Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nature Communications. 8(1). 14572–14572. 270 indexed citations

15.

Jegaskanda, Sinthujan, Catherine J. Luke, Heather D. Hickman, et al.. (2016). Generation and Protective Ability of Influenza Virus–Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. The Journal of Infectious Diseases. 214(6). 945–952. 85 indexed citations

16.

Chai, Ning, Lee R. Swem, Mike Reichelt, et al.. (2016). Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody. PLoS Pathogens. 12(6). e1005702–e1005702. 73 indexed citations

17.

Deng, Rong, Daniela Bumbaca, Cinthia V. Pastuskovas, et al.. (2016). Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. mAbs. 8(3). 593–603. 153 indexed citations

18.

Kalunian, Kenneth, Joan T. Merrill, Romeo Maciuca, et al.. (2015). A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Annals of the Rheumatic Diseases. 75(1). 196–202. 275 indexed citations

19.

Elkins, Kristi, Bing Zheng, MaryAnn Go, et al.. (2012). FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma. Molecular Cancer Therapeutics. 11(10). 2222–2232. 69 indexed citations

20.

Tarner, Ingo H., Anthony Slavin, Jacqueline McBride, et al.. (2003). Treatment of Autoimmune Disease by Adoptive Cellular Gene Therapy. Annals of the New York Academy of Sciences. 998(1). 512–519. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact